Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 35, 2005 - Issue 5
98
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers

, , , , , & show all
Pages 479-486 | Received 11 Jan 2005, Published online: 22 Sep 2008

References

  • Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. 2001. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 40:411–426.
  • Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. 2002. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73:303–304.
  • Ishizaki T, Horai Y. 1999. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Alimentary Pharmacology & Therapeutics 13:27–36.
  • Itoh K, Inoue K, Yanagiwara S, Kyoya H, Suzuki T. 1999. Rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biological & Pharmaceutical Bulletin 22:7–9.
  • Kanazawa H, Okada A, Higaki M, Yokota H, Mashige F, Nakahara K. 2003. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. Journal of Pharmaceutical and Biomedical Analysis 30:1817–1824.
  • Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. 2002. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clinical Pharmacology and Therapeutics 72:90–99.
  • Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF. 1995. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metabolism and Disposition 23:1315–1324.
  • Miura M, Tada H, Suzuki T. 2004a. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. Journal of Chromatography B 804:389–395.
  • Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2004b. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. European Journal of Clinical Pharmacology 60:623–628.
  • Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2005. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. British Journal of Clinical Pharmacology. In press.
  • Nagaya H, Satoh H, Maki Y. 1990. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. Journal of Pharmacology and Experimental Therapeutics 252:1289–1295.
  • Sakai T, Aoyarna N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. 2001. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharmacological Research 18:721–727.
  • Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, et al. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharmacological Research 17:1551–1557.
  • Swan SK, Hoyumpa AM, Merritt GJ. 1999. Review article: the pharmacokinetics of rabeprazole in health and disease. Alimentary Pharmacology & Therapeutics 13:11–17.
  • Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizaki T. 2001. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics 69:108–113.
  • Tateno M, Nakamura N. 1991. Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku 7:51-62 (Japanese).
  • Tybring G, Bottiger Y, Widen J, Bertilsson L. 1997. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clinical Pharmacology and Therapeutics 62:129–137.
  • Yasuda S, Horai Y, Tomono Y, Nakai H, Yarnato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. 1995. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clinical Pharmacology and Therapeutics 58:143–154.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.